Home > Insider Trading > Filing (0001209191-18-022900)

Filing Details

Accession Number:: 0001209191-18-022900
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2018-04-03 16:13:40
Reporting Period:: 2018-04-01

Accepted Time:: 2018-04-03 16:13:40
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1488613	Foundation Medicine Inc.	FMI	Services-Medical Laboratories (8071)	271316416

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1585017	Jason Ryan	150 Second Street C/O Foundation Medicine, Inc. Cambridge MA 02141	Chief Financial Officer	No	Yes	No	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership
Common Stock	Acquisiton	2018-04-01	12,932	$78.75	62,162	No	4	A	Direct
Common Stock	Disposition	2018-04-02	3,109	$77.55	59,053	No	4	S	Direct
Common Stock	Disposition	2018-04-02	3,030	$74.87	56,023	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership
No	4	A	Direct
No	4	S	Direct
No	4	S	Direct

Footnotes

Represents restricted stock units issued pursuant to a Restricted Stock Unit Award Agreement and the Issuer's 2013 Stock Option and Incentive Plan. Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. The restricted stock units vest in equal quarterly installments over a three-year period with the first installment vesting on July 1, 2018.
The sale of these shares were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 7, 2017.
Represents the number of shares required to be sold by the reporting person to cover the tax withholding obligation in connection with the vesting of restricted stock units on April 1, 2018. This sale is mandated by the Issuer's election under its equity incentive plans to require the reporting person to fund this tax withholding obligation by completing a "sell to cover" transaction with a brokerage firm designated by the Issuer. This sale does not represent a discretionary trade by the reporting person.
The price reported in this Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $71.60 to $75.00, inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each price within the ranges set forth in this footnote.
The reporting person previously reported restricted stock units granted to the reporting person on April 1, 2016 in Table I of the Form 4 filed on April 6, 2016. As such, no adjustment to the reporting person's beneficial interest needs to be made to reflect the vesting event related to this securities sale.